Speaking to CNBC-TV18, Shaunak Amin, MD of Alembic Pharma said that there was pricing pressure during the September quarter.
However, he added that they should be able to keep the momentum. “We have enough visibility downstream to kind of see and based on that we have given the EPS (earnings per share) number. I think the business, both US and ex-US, the bulk drug business especially, as well as in the India business we expect to see a strong momentum,” he said.
Amin further added that they are confident of achieving an EPS of Rs 60 this year. “We have invested a large amount in capex in the last 3 years and a lot of these plants would go into pre-operative next year. So, just to give a guidance to say that things are on track we have given this guidance of EPS of Rs 60 and saying that the balance of the year we should be able to perform to these levels. So, we are extremely confident that we will deliver on these numbers,” he said.
On the Production Linked Incentive (PLI) scheme, Amin said that they might apply for the API sector, but they are currently in the process of evaluating the scheme.